Parkinson's Disease Tulip


advertisement
Reply
 
Thread Tools Display Modes
Old 12-11-2006, 05:23 PM #1
paula_w paula_w is offline
In Remembrance
 
Join Date: Aug 2006
Location: Florida
Posts: 3,904
15 yr Member
paula_w paula_w is offline
In Remembrance
 
Join Date: Aug 2006
Location: Florida
Posts: 3,904
15 yr Member
Default FOX Foundation Press Release

Michael J. Fox Foundation Commits Up to $10 Million for LEAPS 2007 Initiative
12/11/2006 1:27:00 PM
To: National Desk
Contact: Holly Barkhymer, 212-509-0995 ext. 242, or hbarkhymer@michaeljfox.org , or Todd Sherer, 212-509-0995 ext. 243, tsherer@michaeljfox.org
NEW YORK, Dec. 11 /U.S. Newswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) has announced the launch of its LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) 2007 funding effort, committing up to $10 million to support ambitious research projects that will translate into new treatments or otherwise have a tangible impact on Parkinson's disease research. LEAPS is a novel research paradigm designed to hasten progress toward better Parkinson's disease therapies and a cure by funding collaborative, milestone-driven approaches to major unanswered research questions.
"LEAPS captured the imagination of the scientific community and attracted innovative and potentially high-impact concepts in 2003 and 2005," said Tim Greenamyre, MD, Ph.D, director of the Pittsburgh Institute for Neurodegenerative Diseases and a member of the MJFF scientific advisory board, who chairs the LEAPS effort. "As the program continues to gain recognition and attention throughout the Parkinson's research field, we are confident that our third outing will catalyze another round of similarly creative and exciting projects."
LEAPS takes a "top-down" approach, requiring that teams start by outlining a particular outcome or set of outcomes they are seeking, and then draft and implement a realistic workplan that can get them to their goal. The program is intended to drive projects encompassing work from proof of principle through Phase II trials. Some of the impressive academic-industry partnerships funded under LEAPS to date have focused on advancing encapsulated cell technology to deliver GDNF, a trophic factor that has shown potential in preclinical trials to slow or stop PD progression; developing a form of gene therapy in which clinicians would be able to control gene expression in a patient's brain following transplantation; and investigating a therapy to inhibit alpha- synuclein, a protein whose overexpression is linked to Parkinson's risk.
"LEAPS is in many ways emblematic of the foundation's overall research strategy," said Deborah W. Brooks, the foundation's president and CEO. "Our focus is on driving the best research into the clinic and to patients. LEAPS leverages academic- industry collaboration and pooled resources to create teams that include experts in every phase of the development pipeline, from discovery work to early clinical research. The model accelerates 'handoffs' that keep promising approaches moving steadily forward."
LEAPS are multi-year, multi-million dollar grants awarded to "all-star" research teams focused on making a major, practical step forward in the treatment of Parkinson's disease. LEAPS investigators interact regularly with MJFF staff and advisors to discuss elements of the project, research directions and progress against stated milestones.
Grants will be awarded based on the potential impact and scientific merit of the chosen research question, probability of success in developing new treatments or otherwise accelerating progress in Parkinson's science, leadership and team track record, as well as other criteria. The foundation expects to invest a total of $10 million; applicants may propose projects lasting up to four years. The number of awards granted ultimately will depend on the scientific merit of proposals received.
Research teams interested in applying should visit the foundation's Web site -- http://www.michaeljfox.org -- for access to the RFP and instructions for submitting the pre-proposal online by 6 p.m. EST on March 20, 2007. Grants are expected to be awarded by August 2007.
LEAPS is a key element of The Michael J. Fox Foundation's aggressive research agenda aimed at accelerating a cure for Parkinson's disease. To date, the foundation has funded $85 million in research directly or through partnerships. For more information, visit http://www.michaeljfox.org.
---
http://www.usnewswire.com/
-0-
/© 2006 U.S. Newswire 202-347-2770/
__________________
paula

"Time is not neutral for those who have pd or for those who will get it."
paula_w is offline   Reply With QuoteReply With Quote

advertisement
Old 12-12-2006, 08:57 PM #2
Howardh's Avatar
Howardh Howardh is offline
Member
 
Join Date: Sep 2006
Location: New Zealand
Posts: 229
15 yr Member
Howardh Howardh is offline
Member
Howardh's Avatar
 
Join Date: Sep 2006
Location: New Zealand
Posts: 229
15 yr Member
Thumbs Up Go Hard

SCIENCE

The message you have entered is too short. Please lengthen your message to at least 10 characters. That should do it.
Howardh is offline   Reply With QuoteReply With Quote
Old 12-12-2006, 09:44 PM #3
jeanb's Avatar
jeanb jeanb is offline
Senior Member
 
Join Date: Aug 2006
Location: sonoran desert
Posts: 1,352
15 yr Member
jeanb jeanb is offline
Senior Member
jeanb's Avatar
 
Join Date: Aug 2006
Location: sonoran desert
Posts: 1,352
15 yr Member
Default Go fox!!

Thanks, Paula. This is GREAT news!
__________________
Jean B

This isn't the life I wished for, but it is the life I have. So I'm doing my best.
jeanb is offline   Reply With QuoteReply With Quote
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off


Similar Threads
Thread Thread Starter Forum Replies Last Post
Gene Variation affects pain sensitivity and risk of chronic pain - NIH press release fmichael Reflex Sympathetic Dystrophy (RSD and CRPS) 2 10-26-2006 06:35 PM
Gene Variation affects pain sensitivity and risk of chronic pain - NIH press release fmichael Chronic Pain 0 10-26-2006 03:35 PM
CAMR Press Release paula_w Parkinson's Disease 0 10-26-2006 01:37 PM
Press release re Lyme Disease Chemar Lyme Disease, Shingles and Other Microbial Conditions 2 10-04-2006 12:11 PM
Claire Collier Act-- Dodd Press Release & Bill Text (S. 3839) BobbyB ALS News & Research 0 09-11-2006 09:29 AM


All times are GMT -5. The time now is 08:43 PM.

Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise v2.7.1 (Lite) - vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.


Always consult your doctor before trying anything you read here.